Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | CCR3 | P51677 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1808312 | 1.00 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1CCR3POLBDRD4 | |
| SCHEMBL1807347 | 0.90 | CCR3 (0.55) | ALDH1A1L3MBTL1CCR3POLBDRD4 | |
| SCHEMBL1807357 | 0.90 | CCR3 (0.55) | ALDH1A1L3MBTL1CCR3POLBDRD4 | |
| SCHEMBL1809981 | 0.90 | ALDH1A1 (0.49) | ALDH1A1L3MBTL1CCR3POLBDRD4 | |
| SCHEMBL1809987 | 0.90 | ALDH1A1 (0.49) | ALDH1A1L3MBTL1CCR3POLBDRD4 | |
| SCHEMBL1813911 | 0.88 | ALDH1A1 (0.49) | ALDH1A1L3MBTL1CCR3POLBDRD4 | |
| SCHEMBL1813903 | 0.88 | ALDH1A1 (0.49) | ALDH1A1L3MBTL1CCR3POLBDRD4 | |
| SCHEMBL1808432 | 0.88 | ALDH1A1 (0.57) | ALDH1A1POLBNPC1RAB9AKMT2A | |
| SCHEMBL1808435 | 0.88 | ALDH1A1 (0.57) | ALDH1A1POLBNPC1RAB9AKMT2A | |
| SCHEMBL1810446 | 0.82 | ALDH1A1 (0.51) | ALDH1A1L3MBTL1CCR3POLBDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160193217-A1 | THERAPEUTIC AGENT FOR OPHTHALMIC DISEASE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-07-07 | — | — | US | claimed |
| EP-1801108-B9 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-11-20 | — | — | EP | claimed |
| EP-1801108-B1 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-11-14 | — | — | EP | claimed |
| US-7935700-B2 | Morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-03 | — | — | US | claimed |
| US-20070265257-A1 | Morpholine Compound | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | claimed |
| EP-1801108-A1 | MORPHOLINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-06-27 | — | — | EP | claimed |
| US-20230312697-A1 | METHODS OF IMPROVING RETINA-ASSOCIATED DISEASE OUTCOME USING CCR3-INHIBITORS | ALKAHEST INC. | 2023-10-05 | — | — | US | disclosed |
| CN-115697334-A | Methods of improving retinal related disease outcomes using CCR3 inhibitors | 万能溶剂有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-10130634-B2 | Therapeutic agent for ophthalmic disease | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-11-20 | — | — | US | disclosed |
| US-20160193217-A1 | THERAPEUTIC AGENT FOR OPHTHALMIC DISEASE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-07-07 | — | — | US | disclosed |
| EP-1801108-B9 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-11-20 | — | — | EP | disclosed |
| EP-1801108-B1 | MORPHOLINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATIONS | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-11-14 | — | — | EP | disclosed |
| US-7935700-B2 | Morpholine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-05-03 | — | — | US | disclosed |
| US-20070265257-A1 | Morpholine Compound | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1801108-A1 | MORPHOLINE COMPOUND | Mitsubishi Pharma Corporation (JP) | 2007-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312697-A1 | METHODS OF IMPROVING RETINA-ASSOCIATED DISEASE OUTCOME USING CCR3-INHIBITORS | CCR3, CCR1, CCRL2 | ALDH1A1 1498/4885L3MBTL1 3103/4885CCR3 1/4885 |
| US-10130634-B2 | Therapeutic agent for ophthalmic disease | MITF, UACA, VEGFA | ALDH1A1 289/4885L3MBTL1 3249/4885CCR3 3110/4885 |
| US-20160193217-A1 | THERAPEUTIC AGENT FOR OPHTHALMIC DISEASE | MITF, UACA, VEGFA | ALDH1A1 289/4885L3MBTL1 3249/4885CCR3 3110/4885 |
| US-20070265257-A1 | Morpholine Compound | CCR3, CCR1, CCR4 | ALDH1A1 2661/4885L3MBTL1 1798/4885CCR3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.